Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Andelyn Biosciences Manufactures Viral Vector

What are you searching for?

Sign in
Breaking News

Andelyn Biosciences Manufactures Viral Vector with AAV Curator Platform

The Adeno-Associated Virus will be used in a Phase 1 trial in patients with advanced, high-risk acute myeloid leukemia.

By: Rachel Klemovitch

Assistant Editor

Andelyn Biosciences, Inc., a patient-focused cell and gene therapy CDMO, has manufactured a viral vector with its AAV Curator Platform for Nationwide Children’s Hospital’s Cellular Therapy and Cancer Immunology Program. 

The Adeno-Associated Virus (AAV) will be utilized in a novel cell therapy for Universal-Donor CD38KO CD33CAR-NK cells, to be studied in a clinical trial. The Phase 1 trial will study the safety of the novel therapy in patients with advanced, high-risk acute myeloid leukemia (AML).

Matt Niloff, Chief Commercial Officer at Andelyn said, “We are excited to be playing a key role in this very promising Universal Donor CD38KO CD33CAR-NK cell therapy technology by NCH. We look forward to the clinical trial and ushering in a new era for patients with AML and other blood cancers.”

Andelyn’s AAV Curator Platform utilizes Optimization-by-Design to be correctly sized for scale and speed to the clinic. The well-established platform allows for the ability to support the exacting viral vector manufacturing needs of the NCH NK cells created on the hospital’s patented universal-donor NK cell platform.

Andelyn is enabling the progression of life-altering cell and gene therapies for rare and prevalent diseases and scalable end-to-end development and manufacturing capabilities at its Columbus, Ohio, facilities.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics